Literature DB >> 20331471

Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells.

Mary Philip1, Andrea Schietinger, Hans Schreiber.   

Abstract

Proteins released from dying cells can be taken up and presented by antigen-presenting cells (APC) to T cells. While the presentation of such self antigens may lead to beneficial anti-tumour responses, in autoimmune disease it leads to pathological immune responses. The sub-set of self proteins targeted in autoimmune disease is circumscribed, and certain cellular components such as ribonucleoprotein (RNP) complexes are often targeted. Although explanations for this antigen selectivity have been proposed, there has been little direct testing of these hypotheses. We and others previously showed that ribosomal proteins, targeted in autoimmune disease, are also targets of anti-tumour T-cell responses. We asked whether particular properties of ribosomal proteins such as incorporation into RNP complexes or sub-cellular localization enhance ribosomal protein presentation by APC to CD4(+) T cells. Ribosomal protein antigens within purified intact ribosomes or free of the ribosomes were equally well taken up and presented by APC, demonstrating that inclusion of ribosomal proteins into an RNP complex does not confer an advantage. However, antigens localized to ribosomes within apoptotic cells were less efficiently taken up and presented by APC than the same antigens localized diffusely throughout the cell. This suggests that presentation of ribosomal proteins is somehow down-regulated, possibly to facilitate presentation of other less-abundant intracellular proteins. Consequently, the explanation for the frequent targeting of ribosomal proteins by both autoimmune and anti-tumour T-cell responses is not at the level of uptake from apoptotic cells and must be sought elsewhere.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331471      PMCID: PMC2913260          DOI: 10.1111/j.1365-2567.2010.03258.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  The role of the zinc finger motif and of the residues at the amino terminus in the function of yeast ribosomal protein YL37a.

Authors:  John Dresios; Yuen-Ling Chan; Ira G Wool
Journal:  J Mol Biol       Date:  2002-02-22       Impact factor: 5.469

Review 2.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules?

Authors:  J W Yewdell; L C Antón; J R Bennink
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

3.  Lethality-based selection of recombinant genes in mammalian cells: application to identifying tumor antigens.

Authors:  E S Smith; A Mandokhot; E E Evans; L Mueller; M A Borrello; D M Sahasrabudhe; M Zauderer
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

4.  Acidic ribosomal P proteins are phosphorylated in Trypanosoma cruzi.

Authors:  E B Gómez; G Medina; J P Ballesta; M J Levin; M T Téllez-Iñón
Journal:  Int J Parasitol       Date:  2001-08       Impact factor: 3.981

5.  Immunochemical analysis of an arginine-rich systemic lupus erythematosus autoepitope.

Authors:  S Pelsue; K D Jung; P F Agris
Journal:  Autoimmunity       Date:  1993       Impact factor: 2.815

6.  Basic amino acids predominate in the sequential autoantigenic determinants of the small nuclear 70K ribonucleoprotein.

Authors:  J A James; R H Scofield; J B Harley
Journal:  Scand J Immunol       Date:  1994-06       Impact factor: 3.487

7.  A leucine zipper-like motif and a basic region-leucine zipper-like element in rat ribosomal protein L13a. Identification of the tum- transplantation antigen P198.

Authors:  Y L Chan; J Olvera; A Glück; I G Wool
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

8.  Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.

Authors:  C Sibille; P Chomez; C Wildmann; A Van Pel; E De Plaen; J L Maryanski; V de Bergeyck; T Boon
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.

Authors:  G B Beck-Engeser; P A Monach; D Mumberg; F Yang; S Wanderling; K Schreiber; R Espinosa; M M Le Beau; S C Meredith; H Schreiber
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

View more
  5 in total

1.  Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY.

Authors:  Sascha Kretschmann; Stefanie Herda; Heiko Bruns; Josefine Russ; Edith D van der Meijden; Ursula Schlötzer-Schrehardt; Marieke Griffioen; Il-Kang Na; Andreas Mackensen; Anita N Kremer
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

2.  A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature.

Authors:  N Russo; X Wang; M Liu; R Banerjee; M Goto; C Scanlon; T Metwally; R C Inglehart; A Tsodikov; S Duffy; E Van Tubergen; C Bradford; T Carey; G Wolf; A M Chinnaiyan; N J D'Silva
Journal:  Oncogene       Date:  2012-11-19       Impact factor: 9.867

3.  Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.

Authors:  Allan NoeDominguez-Romero; Rubén Zamora-Alvarado; Rodolfo Servín-Blanco; Erendira G Pérez-Hernández; Laura E Castrillon-Rivera; Maria Elena Munguia; Gonzalo Acero; Tzipe Govezensky; Goar Gevorkian; Karen Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

5.  Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.

Authors:  Andrea Schietinger; Mary Philip; Rebecca B Liu; Karin Schreiber; Hans Schreiber
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.